NSD2 is a HKMT which triggers the expression of oncogenes and the oncogenic programming in an aggressive type of multiple myeloma tumors, affecting 15 to 20% of multiple myeloma patients.
This program has received research grants from the European Community Eurostars program which has selected the EMTherapies consortium (Therapeutic use of Epigenetic Modulators in oncological and neurodegenerative disease),constituted by three European biotechs involved in epigenetic research including Inventiva. Press release

Primary Indication

  • Multiple myeloma